Navigation Links
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon's product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer's.

Gordon McCauley, Allon's President and Chief Executive Officer, announced this publication to a conference in New York sponsored by investment bank Leerink Swann & Company entitled "A Mind is a Terrible Thing to Waste: Emerging Trends for Alzheimer's Disease." The invitation only event for institutional investors, venture capitalists and hedge fund managers who invest in the healthcare sector, highlights select companies developing Alzheimer's treatments.

"Our Alzheimer's program is based on this very compelling data showing that our compounds work on both of the classic hallmarks of Alzheimer's disease and the Phase II efficacy program is enrolling well," said McCauley. "We believe that we have implemented a sound and strategically balanced clinical plan for our compounds and we anticipate the results eagerly."

"Data published in The Journal of Molecular Neuroscience shows that AL-108 can modify disease progression in one of the most relevant models of Alzheimer's disease and our clinical development program is working to demonstrate this capability in human clinical trials," McCauley said.

McCauley said Allon is focused on developing drugs to treat processes underlying numerous neurodegenerative diseases and injury of the central nervous system. Drugs on the market today treat only the symptoms of these diseases and conditions.

Webcast and Conference location

Allon Therapeutics' presentation will take place on Tuesday, April 3, 2007 at 2:15pm Ea
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
(Date:5/29/2015)... 29, 2015  Excite Medical was established by its ... years, Excite Medical, under the leadership of Mr. ... with a solid track record of providing unparalleled service ... distributor base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... has been possible, in large part, due to ...
(Date:5/29/2015)... BRUNSWICK, N.J. , May 29, 2015 ... start-up companies originally funded with investments from Foundation Venture ... research at Bio International 2015 as part of the ... Conference, announced FVCG President James M. Golubieski . ... for the biotechnology industry, will be held in ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Oct. 11 Essentialis, Inc. announced today that the ... has issued U.S. Patent No. 7,799,777 entitled Salts ... The patent claims a novel composition of a polymorph ... lead product, DCCR.  Essentialis has successfully completed phase 2b ...
... 11 Pioneer Surgical Technology, Inc., a leader ... plan to establish a manufacturing and distribution facility ... IDA (Ireland Development Authority) to evaluate potential sites ... facility will support Pioneer,s continued growth in Europe ...
Cached Medicine Technology:Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio 2PioneerĀ® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland 2
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
(Date:5/30/2015)... Michigan (PRWEB) May 30, 2015 NovaSure® ... to lighten or stop periods, without the side ... procedure can reduce or stop menstrual bleeding and works ... uterus (the part that causes the bleeding), with a ... women suffer from heavy menstrual bleeding. Many women ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4
... ... in a new, or remodeled home, built between 2004, and 2008, in ... numerous air conditioning problems, combined with health issues, the Chinese Drywall Complaint ... toxic Chinese drywall being the culprit. The new major focus areas are ...
... ... selected the Atlanta-based IT support and service company to manage IT services and hosting ... ... Atlanta’s fastest growing managed IT services company, announced today that Marietta Eye Clinic ...
... ... CellTrak’s latest clients, Community Home Support Services Association (CHSSA) supports elderly ... CHSSA provides a variety of health care services during in-home client ... were recorded on paper along with older technologies, like voicemail, copies ...
... WEEKEND ADMISSION TO ICU MAY INCREASE RISK OF DEATH ... may have an increased risk of death compared with ... of Philadelphia, Philadelphia, PA, and Eastern Virginia Medical School, ... association between time of admission to the ICU and ...
... Abuse and neglect during childhood appear to be associated with ... young adults, according to a report in the June issue ... JAMA/Archives journals. Most studies of child maltreatment and later ... according to background information in the article. Doubts have been ...
... MONDAY, July 5 (HealthDay News) -- Too much time spent ... of attention problems in children and young adults, new research ... point out the ill effects of excessive screen time, whether ... a graduate student at Iowa State University, compared participants who ...
Cached Medicine News:Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 2Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 3Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 4Health News:Marietta Eye Clinic Selects BlueWave Computing for IT Support and Hosting 2Health News:Marietta Eye Clinic Selects BlueWave Computing for IT Support and Hosting 3Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 2Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 3Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 4Health News:News briefs from the July issue of Chest 2Health News:Abused children appear likely to have mental disorders as young adults 2Health News:Too Much Screen Time Can Threaten Attention Span 2Health News:Too Much Screen Time Can Threaten Attention Span 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: